From Health Canada:
Hoffmann-La Roche Limited, in consultation with Health Canada, has informed Canadian healthcare professionals of important new safety information concerning RITUXAN (rituximab).
RITUXAN is authorized in Canada for the treatment of non-Hodgkin’s lymphoma (a cancer of the lymph nodes) and rheumatoid arthritis (an inflammatory disease of the joints).
For health care professionals
For the public
Showing posts with label rituximab. Show all posts
Showing posts with label rituximab. Show all posts
Monday, August 13, 2007
Subscribe to:
Posts (Atom)